COMMUNIQUÉS West-GlobeNewswire

Néovacs renforce sa structure financière
25/03/2019
COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE NÉOVACS RENFORCE SA STRUCTURE FINANCIÈRE: ÉMISSION D'«ORNANE» POUR UN MONTANT MAXIMUM DE €10M, SANS BONS DE SOUSCRIPTION D'ACTIONS Paris et Boston, le [...]
Neovacs reports full-year 2018 Financial results and provides corporate update
25/03/2019
RESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS REPORTS FULL-YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE KEY OPINION LEADERS VALIDATE THE THERAPEUTIC POTENTIAL OF IFNα KINOID IN LUPUS TREATMENT [...]
Néovacs annonce ses résultats annuels 2018 et fait le point sur ses activités
25/03/2019
COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE NÉOVACS ANNONCE SES RÉSULTATS ANNUELS 2018 ET FAIT LE POINT SUR SES ACTIVITÉS VALIDATION PAR LES EXPERTS SCIENTIFIQUES DU POTENTIEL THÉRAPEUTIQUE DE L’ [...]
Dermira Announces “Life Unfolds” Direct-to-Consumer Campaign to Highlight QBREXZA™ (glycopyrronium) Cloth
25/03/2019
New multichannel consumer campaign will feature QBREXZA patients Campaign to drive consumer awareness of QBREXZA QBREXZA is the first and only FDA-approved, once-daily, topical prescription treatment indicated for [...]
REVA Receives Interim Funding Commitment and Announces Leadership Changes
25/03/2019
SAN DIEGO, March 24, 2019 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) said today that it has secured a letter of commitment for up to $3 million of debt financing to fund operations on an [...]
MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive Multiple Sclerosis at the 71st American Academy of Neurology Annual Meeting in Philadelphia, Pennsylvania
25/03/2019
LA JOLLA, Calif., March 24, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), [...]
Ascendis Pharma Announces Phase 3 heiGHt Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon™ hGH to a Daily Growth Hormone
24/03/2019
- Oral presentation of results in pediatric growth hormone deficiency on behalf of investigators at ENDO 2019 - - Patient group acknowledges importance of once-weekly therapy to address overall impact of GHD - [...]
Developing Better Athletes through Optometry
24/03/2019
ANDERSON, S.C., March 24, 2019 (GLOBE NEWSWIRE) -- There's a new game in town called Sports Vision EyeQ, by RightEye. It is a comprehensive way to measure, analyze, and correct eye movements, giving vision that goes [...]
Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO
23/03/2019
New Orleans, US , 23 March 2019 - Oral semaglutide 7 mg and 14 mg demonstrated superior HbA 1c and body weight reductions compared to Januvia ® (sitagliptin 100 mg). Non-inferiority for oral semaglutide 3 mg for HbA 1c [...]
Radius Health Presents Analysis from Phase 3 ACTIVE Trial and Data from Preclinical Studies for TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting
23/03/2019
-Post-hoc analysis suggests abaloparatide may be useful in the treatment of women with postmenopausal osteoporosis and concurrent osteoarthritis, at high risk for fracture- -Preclinical studies provide explanations for [...]
InspireMD Provides Amended Disclosure
22/03/2019
TEL AVIV, Israel, March 22, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery [...]
Healthcare Special Opportunities Fund Announces March 2019 Quarterly Distribution
22/03/2019
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, March 22, 2019 (GLOBE NEWSWIRE) -- ( TSX: MDS.UN ) – LDIC Inc. (the “ Manager ”), the manager of Healthcare Special [...]
U.S. Healthcare Leader Joseph R. Swedish Appointed Mesoblast Chairman
22/03/2019
NEW YORK and MELBOURNE, Australia, March 22, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today announced it has appointed Joseph R. Swedish as non-executive Chairman. Mr Swedish will succeed [...]
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22/03/2019
WALTHAM Mass., and CRESTWOOD, Ky., March 22, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]
Neuralstem Reports Year End 2018 Fiscal Results
22/03/2019
GERMANTOWN, Md., March 22, 2019 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule [...]
Y-mAbs Announces 2018 Financial Results and Corporate Development Highlights
22/03/2019
NEW YORK, March 22, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel [...]
IntelGenx Reports Fourth Quarter and Full-Year 2018 Financial Results
22/03/2019
SAINT LAURENT, Quebec, March 22, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results for the fourth quarter and twelve-month [...]
Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
22/03/2019
MENLO PARK, Calif., March 22, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies [...]
BioSyent Announces Notice of Deficiency for Cardiovascular Products
22/03/2019
TORONTO, March 22, 2019 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that it has been informed by Health Canada that the Company will receive a Notice of Deficiency (“NOD”) [...]

Pages